{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:09Z","timestamp":1793119629098,"version":"4.5.0"},"reference-count":49,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic obstructive pulmonary disease (COPD) is a progressive lung disease marked by airway inflammation and obstruction. Ensifentrine is a novel inhaled PDE3 and PDE4 inhibitor with both bronchodilator and anti-inflammatory effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Comprehensively review the available evidence on ensifentrine and its potential role in COPD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis with trial sequential analysis of randomized clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Scopus, ScienceDirect, Cochrane Library, and Medline for clinical trials published between 2018 and August 2024 that evaluated the safety and efficacy of ensifentrine in patients with COPD. We assessed study quality using the RoB 2 tool and conducted the meta-analysis with the \u201cmeta\u201d package in R (version 4.3.2), using the mean difference with a 95% confidence interval to evaluate changes in outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five studies met the predefined inclusion criteria with 2519 participants. At week 12, the pooled analysis indicated that forced expiratory volume in 1\u2009s (FEV\n                      <jats:sub>1<\/jats:sub>\n                      ) and trough FEV\n                      <jats:sub>1<\/jats:sub>\n                      were significantly increased in the ensifentrine group (mean difference (MD): 91.32; 95% CI: 69.63 to 113.01) and (MD: 40.90; 95% CI: 19.65 to 62.15), respectively. At week 24, the pooled analysis indicated that the evaluating respiratory symptoms total score was significantly decreased in the ensifentrine group (MD: \u22120.81; 95% CI: \u22121.36 to \u22120.27), transition dyspnea index score was significantly increased in the ensifentrine group (MD: 0.96; 95% CI: 0.62 to 1.29), no significant difference was observed in rescue medication use (MD: \u22120.30; 95% CI: \u22120.60 to 0.00), and no significant difference was observed in St. George\u2019s Respiratory Questionnaire total score (MD: \u22121.46; 95% CI: \u22123.22 to 0.30). Based on subgroup analysis, higher doses were associated with more favorable results.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In conclusion, owing to its dual effects, ensifentrine has a significant impact on improving pulmonary function and quality of life with minimal side effects. Promising results are expected if implied by synergizing with other drugs, however, more studies are needed to study the long-term effect on disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>The study protocol was published via PROSPERO: International Prospective Register of Systematic Reviews (#CRD42024570799).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17534666251347775","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T03:20:26Z","timestamp":1750389626000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of ensifentrine in treatment of COPD: a systematic review and meta-analysis of clinical trials"],"prefix":"10.1177","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1025-1068","authenticated-orcid":false,"given":"Bara M.","family":"Hammadeh","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Al-Balqa\u2019 Applied University, Salt 11185, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1027-554X","authenticated-orcid":false,"given":"Osama M.","family":"Younis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muaath I.","family":"Alsufi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-8214","authenticated-orcid":false,"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Lahore General Hospital, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayham Mohammad","family":"Hussein","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Balqa\u2019 Applied University, Salt, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2260-0326","authenticated-orcid":false,"given":"Abdullah Yousef","family":"Aldalati","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6017-2861","authenticated-orcid":false,"given":"Fares A.","family":"Qtaishat","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banan","family":"Qatawneh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Al-Balqa\u2019 Applied University, Salt, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al","family":"Bugazia","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin, Madison, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed A.","family":"Hamed","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA"},{"name":"Aurora Sinai Medical Center, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"e_1_3_4_2_2","volume-title":"StatPearls","author":"Agarwal AK","year":"2025","unstructured":"Agarwal AK, Raja A, Brown BD. Chronic obstructive pulmonary disease. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2025."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33311-1"},{"key":"e_1_3_4_4_2","volume-title":"StatPearls","author":"Widysanto A","year":"2025","unstructured":"Widysanto A, Goldin J, Mathew G. Chronic bronchitis. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2025."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201210-1843CI"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00170.x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14451.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-17969-3_17"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61255-1"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-01512-y"},{"key":"e_1_3_4_11_2","unstructured":"U.S. Food and Drug Administration. Drug label: NDA 022522\/S009\u2014Roflumilast. Highlights of prescribing information label."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.02.002"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70187-5"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01074-2018"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101814"},{"key":"e_1_3_4_16_2","article-title":"A phase I, randomised, double blind, placebo controlled, study to assess the safety, tolerability and pharmacokinetics of multiple inhaled doses of RPL554 administered by nebuliser to healthy male subjects and stable COPD patients","volume":"193","author":"Singh D","year":"2016","unstructured":"Singh D, Abbott-Banner KH, Reid F, et al. A phase I, randomised, double blind, placebo controlled, study to assess the safety, tolerability and pharmacokinetics of multiple inhaled doses of RPL554 administered by nebuliser to healthy male subjects and stable COPD patients. Am J Respir Crit Care Med 2016; 193: A6838.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S154012"},{"key":"e_1_3_4_18_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_4_19_2","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston M","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019; 10: ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_20_2","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ; 366: l4898.","journal-title":"BMJ"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_3_4_22_2","volume-title":"User manual for trial sequential analysis (TSA)","author":"Thorlund K","year":"2017","unstructured":"Thorlund K, Engstr\u00f8m J, Wetterslev J, et al. User manual for trial sequential analysis (TSA). 2nd ed. Copenhagen: Copenhagen Trial Unit, 2017.","edition":"2"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-0944OC"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S307160"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-020-1307-4"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2023.2292613"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0303-8"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S419056"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.657596"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25194437"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S413436"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.1656"},{"key":"e_1_3_4_33_2","article-title":"Effects of additional oral theophylline with inhaled therapy in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"20","author":"Yang Q","year":"2025","unstructured":"Yang Q, Tang P, Zhang X, et al. Effects of additional oral theophylline with inhaled therapy in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. PLoS One 2025; 20: e0321984.","journal-title":"PLoS One"},{"key":"e_1_3_4_34_2","unstructured":"Rickard K Darpo B Xue H et al. The dual phosphodiesterase (PDE) 3 and 4 inhibitor ensifentrine does not prolong QT interval in healthy volunteers. B39 COPD Management: From Pharmacologic Treatment to Novel Therapies. https:\/\/www.atsjournals.org\/doi\/abs\/10.1164\/ajrccm-conference.2022.205.1_meetingabstracts.a5605"},{"key":"e_1_3_4_35_2","unstructured":"Rickard K Bengtsson T Rheault T. Cardiovascular safety profile of ensifentrine in patients with COPD: results from two four-week dose-ranging randomized placebo-controlled trials. TP040 COPD Clinical Trials and Therapies. https:\/\/www.atsjournals.org\/doi\/abs\/10.1164\/ajrccm-conference.2021.203.1_meetingabstracts.a2256"},{"key":"e_1_3_4_36_2","article-title":"Rpl554, a dual phosphodiesterase (PDE) 3\/4 inhibitor acts synergistically with muscarinic receptor antagonists and beta-adrenoceptor agonists to produce bronchodilation in vivo","author":"Keir S","unstructured":"Keir S, Page C. Rpl554, a dual phosphodiesterase (PDE) 3\/4 inhibitor acts synergistically with muscarinic receptor antagonists and beta-adrenoceptor agonists to produce bronchodilation in vivo. C32 Asthma: Pre-Clinical Studies.","journal-title":"C32 Asthma: Pre-Clinical Studies"},{"key":"e_1_3_4_37_2","first-page":"576","article-title":"Interpreting evaluating respiratory symptomsTM in COPD diary scores in clinical trials: terminology, methods, and recommendations","volume":"9","author":"Leidy NK","year":"2022","unstructured":"Leidy NK, Bushnell DM, Thach C, et al. Interpreting evaluating respiratory symptomsTM in COPD diary scores in clinical trials: terminology, methods, and recommendations. Chronic Obstr Pulm Dis 2022; 9: 576\u2013590.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S263025"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0372-1"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62410-7"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201607-1349OC"},{"key":"e_1_3_4_42_2","first-page":"382","article-title":"Design of the redefining therapy in early COPD study","volume":"7","author":"Han MK","year":"2020","unstructured":"Han MK, Ye W, Kim DY, et al. Design of the redefining therapy in early COPD study. Chronic Obstr Pulm Dis 2020; 7: 382\u2013389.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.04.013"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202308-1355LE"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.08.002"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.10.002"},{"key":"e_1_3_4_47_2","first-page":"298","article-title":"Short-term impact of the frequency of COPD exacerbations on quality of life","volume":"9","author":"Camac ER","year":"2022","unstructured":"Camac ER, Stumpf NA, Helen K. Voelker, et al. Short-term impact of the frequency of COPD exacerbations on quality of life. Chronic Obstr Pulm Dis 2022; 9: 298\u2013308.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"e_1_3_4_48_2","unstructured":"Rheault T Rickard K Boscia JA et al. Ensifentrine a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor provides effective bronchodilation in COPD When administered twice daily over 7 days via a dry powder inhaler. B103 Treatment of Obstructive Lung Disease. https:\/\/www.atsjournals.org\/doi\/abs\/10.1164\/ajrccm-conference.2020.201.1_meetingabstracts.a4296"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00181-2021"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00461-7"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251347775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17534666251347775","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17534666251347775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:18:36Z","timestamp":1767687516000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17534666251347775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"alternative-id":["10.1177\/17534666251347775"],"URL":"https:\/\/doi.org\/10.1177\/17534666251347775","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/17534666251347775\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/17534666251347775\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17534666251347775"}}